Phase 2
N=50
Randomized Study of Yohimbine Treatment for Type 2 Diabetes Patients Carrying a Specific Genetic Risk Variant
Type 2 Diabetes
Bottom Line
View on ClinicalTrials.gov: NCT01593215 ↗Enrolled (actual)
50
Serious AEs
1.0%
Results posted
Jan 2015
Primary outcome: Primary: Insulin Secretion — 5; 29 % increase of Ins30
Study Design & Population
- Study type
- Interventional
- Phase
- Phase 2
- Interventions
- Yohimbine (Drug)
- Age
- Adult, Older Adult · 18+ yrs
- Sex
- All
- Sponsor
- Anders Rosengren, MD PhD
- Primary completion
- Oct 2014
Outcome Measures
| Outcome | Result | p-value |
|---|---|---|
| PRIMARY Insulin Secretion |
5; 29 | — |
| SECONDARY Glucose |
— | — |
Summary
The investigators have recently discovered a genetic variant in an adrenergic receptor that leads to increased risk for type 2 diabetes. The investigators have also seen that blockers of that receptor improves impaired insulin secretion in animals. The investigators will now test the blocker in patients with type 2 diabetes with or without the risk variant in an effort to make diabetes treatment more individualized.
Eligibility Criteria
Inclusion Criteria
- type 2 diabetes
- informed consent
- age 18-70, for females only postmenopausal
Exclusion Criteria
- heart disease
- anxiety disorder
- antidiabetic treatment other than metformin
- adrenergic blockers
- ulcus
- allergy to any component in the capsules
Data sourced from ClinicalTrials.gov (NCT01593215). Outcome figures and adverse-event rates are extracted automatically from the registry's posted results and are provided for clinician reference, not as a substitute for the primary publication.